ClinicalTrials.gg
CompletedNCT00166504Updated May 22, 2024Results posted

Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)

A Phase 4 interventional study of ezetimibe (+) simvastatin and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
37th of 97
203 · median 148
Started
2005
with 13 others
Phase 4
31 of 98
1 open now
Registered
9th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 37th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 31 in phase 4, and was the 9th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea. The primary hypothesis being tested is that daily administration of Vytorin will result in a greater reduction of low density lipoprotein cholesterol (LDL-C) concentration from baseline after 6 weeks treatment compared to atorvastatin.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of hypercholesterolemia
  • LDL-C >/= 130 mg/dL but \</=250 mg/dL and triglyceride (TG) \</= 350 mg/dL
  • National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guideline

Exclusion criteria

Exclusion Criteria:

  • to 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitors or Ezetimibe
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Vytorin

    Ezetimibe 10 mg/Simvastatin 20 mg

    Drug: ezetimibe (+) simvastatin

  • Active comparator
    Atorvastatin

    Atorvastatin 10 mg

    Drug: atorvastatin

Interventions

  • Drugezetimibe (+) simvastatin

    Drug pages: Ezetimibe · Simvastatin

    simvastatin/ezetimibe 10/20 mg

    Also known as: MK0653A, Vytorin®

  • atorvastatin 10 mg

    Also known as: Lipitor®

06

What researchers measure

Primary outcomes

  1. LDL-C Lowering Efficacy

    LDL-C = low density lipoprotein cholesterol, measured in mg/dl.

    Time frame: 6 weeks

07

Results

Posted Nov 5, 2008

Participant flow

Participant flow — Overall Study
MilestoneVytorinAtorvastatin
Started10895
Completed10391
Not completed54
Withdrew: Adverse event33
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryLDL-C Lowering Efficacy

LDL-C = low density lipoprotein cholesterol, measured in mg/dl.

Time frame:
6 weeks
Reported as:
Least squares mean · Percent Change from Baseline
LDL-C Lowering Efficacy
Percent Change from BaselineVytorinAtorvastatin
LDL-C Lowering Efficacy-51 ± 14.7-41 ± 16
Statistical analysis
  • Vytorin vs Atorvastatin · ANOVA · p = <0.001 · Mean difference (net): -10 · 95% CI -14.3 to -5.7Direction of the Comparison: Vytorin minus Atorvastatin.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vytorin—0/108 (0%)0/108 (0%)
Atorvastatin—0/95 (0%)0/95 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)VytorinAtorvastatinTotal
Mean58.4 ± 10.758.7 ± 8.758.5 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)VytorinAtorvastatinTotal
Female5756113
Male513990
Baseline Low Density Lipoprotein Cholesterol (LDL-C) Strata
Baseline Low Density Lipoprotein Cholesterol (LDL-C) Strata(Participants)VytorinAtorvastatinTotal
<130 mg/dl235
>=130 to <160 mg/dl453277
>=160 to <190 mg/dl414384
>=190 mg/dl201737
Body Mass Index
Body Mass Index(kg/m2)VytorinAtorvastatinTotal
Mean25.3 ± 2.925 ± 2.825.2 ± 2.8
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2008, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 14, 2005
Start
Oct 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Nov 5, 2008
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00166504
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 14, 2005
Start date
Oct 2005
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Nov 5, 2008
Last update
May 22, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion